Risk factor
Very poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Nexstim Plc, a medical technology company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company's proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers NBT system, a navigated brain therapy system for the treatment of major depression and chronic neuropathic pain; and NBS system, a navigated brain stimulation system for pre-surgical mapping of the speech and motor cortices of the brain. The company primarily sells its NBS systems to universities and teaching hospitals. Nexstim Plc was founded in 2000 and is headquartered in Helsinki, Finland.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Target Price
The average target price of NXTMH.HE is 12 and suggests 26% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell